Litcius/Paper detail

Adding Alirocumab to Rosuvastatin Helps Reduce the Vulnerability of Thin-Cap Fibroatheroma

Yoichiro Sugizaki, Hiromasa Otake, Hiroyuki Kawamori, Takayoshi Toba, Yuichiro Nagano, Yoshiro Tsukiyama, Kenichi Yanaka, Hiroyuki Yamamoto, Akira Nagasawa, Hiroyuki Onishi, Ryo Takeshige, Shinsuke Nakano, Yoichiro Matsuoka, Kosuke Tanimura, Yu Takahashi, Yusuke Fukuyama, Toshiro Shinke, Tatsuro Ishida, Ken-ichi Hirata

2020JACC. Cardiovascular imaging40 citationsDOI

Topics & Concepts

RosuvastatinAlirocumabPCSK9KexinMedicineProprotein convertaseStatinEvolocumabSubtilisinInternal medicineRosuvastatin CalciumAtorvastatinRandomized controlled trialIncidence (geometry)PharmacologyCholesterolLDL receptorLipoproteinChemistryBiochemistryEnzymeOpticsPhysicsApolipoprotein A1Cardiac tumors and thrombiProtease and Inhibitor MechanismsPeptidase Inhibition and Analysis
Adding Alirocumab to Rosuvastatin Helps Reduce the Vulnerability of Thin-Cap Fibroatheroma | Litcius